健康成人接种灭活全病毒颗粒SARS-CoV-2疫苗TURKOVAC的安全性与免疫原性:随机双盲安慰剂对照1期和2期试验的中期结果
该随机双盲安慰剂对照单中心1期和2期试验评估了灭活全病毒颗粒SARS-CoV-2疫苗ERUCoV-VAC在健康成人中的安全性与免疫原性。1期44人和2期250人分别接种3 μg、6 μg或安慰剂,两剂间隔21天(2期28天)。两剂次3 μg和6 μg组安全性可接受,中和抗体应答和血清转换率(第43天和第60天均超过95%)相近。
要点
- 1期试验中3 μg和6 μg组安全性事件无剂量反应关系(p=0.4905)。
- 2期试验中仅注射部位疼痛在疫苗组显著高于安慰剂组(p=0.0322)。
- 两剂次3 μg和6 μg组中和抗体GMT和血清转换率均相近,无显著差异。
核心结论
- 两剂次ERUCoV-VAC 3 μg和6 μg(间隔28天)均具有可接受的安全性和耐受性,并诱导相近的中和抗体应答,首次接种后第43天和第60天血清转换率超过95%。
研究设计与样本
- 双盲、随机、单中心1期和2期试验,纳入18-55岁(2期18-64岁)SARS-CoV-2血清阴性的健康成人。
- 1期44人(3 μg组17人、6 μg组17人、安慰剂组10人),2期250人(3 μg组100人、6 μg组100人、安慰剂组50人)。
- 参与者按计算机生成的随机方案接受两剂肌肉注射ERUCoV-VAC 3 μg或6 μg(含铝佐剂灭活疫苗)或安慰剂,间隔21天(2期28天)。
主要发现
- 1期试验中,截至第43天,15名参与者(34.1%)发生25例不良事件(80%为轻度);注射部位疼痛是最常见不良事件(9/44;20.5%)。
- 1期试验中,3 μg组与6 μg组MNT50中和抗体GMT(95%CI)在第43天分别为8.3(6.4-10.3)和8.6(7.0-10.2)(p=0.7357),第60天分别为9.7(6.0-13.4)和10.8(8.8-12.8)(p=0.8644)。
- 1期试验中,3 μg组与6 μg组FRNT50中和抗体GMT(95%CI)在第43天分别为8.4(6.3-10.5)和9.0(7.2-10.8)(p=0.5393),第60天分别为11.0(7.0-14.9)和12.3(10.3-14.5)(p=0.8578)。
- 1期试验中,3 μg组与6 μg组中和抗体血清转换率(95%CI)在第43天分别为86.7%(59.5-98.3)和94.1%(71.3-99.8)(p=0.8727),第60天分别为92.8%(66.1-99.8)和100%(79.4-100.0)(p=0.8873)。
- 2期试验中,153名参与者(61.2%)发生268例不良事件(67.2%为中度);最常见局部不良事件为注射部位疼痛(21名受试者中23例,8.4%),最常见全身不良事件为头痛(47名受试者中56例,18.8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Development of safe and effective vaccine options is crucial to the success of fight against COVID-19 pandemic. Herein, we report interim safety and immunogenicity findings of the phase 1&2 trials of ERUCoV-VAC, an inactivated whole virion SARS-CoV-2 vaccine. METHODS: Double-blind, randomised, single centre, phase 1 and 2 trials included SARS-CoV-2 seronegative healthy adults aged 18-55 years (18-64 in phase 2). All participants, except the first 4 in phase 1 who received ERUCoV-VAC 3 μg or 6 μg unblinded and monitored for 7 days for safety purposes, were assigned to receive two intramuscular doses of ERUCoV-VAC 3 μg or 6 μg (an inactivated vaccine containing alhydrogel as adjuvant) or placebo 21 days apart (28 days in phase 2) according to computer-generated randomisation schemes. Both trials are registered at ClinicalTrials.gov (phase 1, NCT04691947 and phase 2, NCT04824391). RESULTS: Forty-four participants (3 μg [n:17], 6 μg [n:17], placebo [n:10]) in phase 1 and 250 (3 μg [n:100], 6 μg [n:100], placebo [n:50]) in phase 2 received ≥1 dose. In phase 1 trial, 25 adverse events AEs (80 % mild) occured in 15 participants (34.1 %) until day 43. There was no dose-response relationship noted in safety events in ERUCoV-VAC recipients (p = 0.4905). Pain at injection site was the most common AE (9/44;20.5 %). Both doses of ERUCoV-VAC 3 μg and 6 μg groups were comparable in inducing SARS-CoV-2 wild-type neutralising antibody (MNT50): GMTs (95 %CI) were 8.3 (6.4-10.3) vs. 8.6 (7.0-10.2) at day 43 (p = 0.7357) and 9.7 (6.0-13.4) vs. 10.8 (8.8-12.8) at day 60 (p = 0.8644), respectively. FRNT50 confirmed MNT50 results: SARS-CoV-2 wild-type neutralising antibody GMTs (95 %CI) were 8.4 (6.3-10.5) vs. 9.0 (7.2-10.8) at day 43 (p = 0.5393) and 11.0 (7.0-14.9) vs. 12.3 (10.3-14.5) at day 60 (p = 0.8578). Neutralising antibody seroconversion rates (95 %CI) were 86.7 % (59.5-98.3) vs 94.1 % (71.3-99.8) at day 43 (p = 0.8727) and 92.8 % (66.1-99.8) vs. 100 % (79.4-100.0) at day 60 (p = 0.8873), in ERUCoV-VAC 3 μg and 6 μg groups, respectively. In phase 2 trial, 268 AEs, (67.2 % moderate in severity) occured in 153 (61.2 %) participants. The most common local and systemic AEs were pain at injection site (23 events in 21 [8.4 %] subjects) and headache (56 events in 47 [18.8 %] subjects), respectively. Pain at injection site was the only AE with a significantly higher frequency in the ERUCoV-VAC groups than in the placebo arm in the phase 2 study (p = 0.0322). ERUCoV-VAC groups were comparable in frequency of AEs (p = 0.4587). ERUCoV-VAC 3 μg and 6 μg groups were comparable neutralising antibody (MNT50): GMTs (95 %CI) were 30.0 (37.9-22.0) vs. 34.9 (47.6-22.1) at day 43 (p = 0.0666) and 34.2 (23.8-44.5) and 39.6 (22.7-58.0) at day 60, (p = 0.2166), respectively. FRNT50 confirmed MNT50 results: SARS-CoV-2 wildtype neutralising antibody GMTs were 28.9 (20.0-37.7) and 30.1 (18.5-41.6) at day 43 (p = 0.3366) and 34.2 (23.8-44.5) and 39.6 (22.7-58.0) at day 60 (p = 0.8777). Neutralising antibody seroconversion rates (95 %CI) were 95.7 % (91.4-99.8) vs. 98.9 % (96.9-100.0) at day 43 (p = 0.8710) and 96.6 % (92.8-100.0) vs 98.9 % (96.7-100.0) at day 60 (p = 0.9129) in ERUCoV-VAC 3 μg and 6 μg groups, respectively. CONCLUSIONS: Two-dose regimens of ERUCoV-VAC 3 μg and 6 μg 28 days both had an acceptable safety and tolerability profile and elicited comparable neutralising antibody responses and seroconversion rates exceeding 95 % at day 43 and 60 after the first vaccination. Data availability Data will be made available on request.
引用
- Ozdarendeli A, Sezer Z, Pavel STI, et al. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials. Vaccine. 2022. PMID: 36460536. doi:10.1016/j.vaccine.2022.10.093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。